ICAP’s Bronx Prevention Center (BPC) is in a storefront medical office that is dedicated to clinical research.  Although BPC has been in the South Bronx for the last 25 years, for the last 15 years, it has been  a part of ICAP’s Clinical Trials Unit, advancing vision of healthy people, empowered communities and thriving societies.  Although BPC does not provide routine healthcare services, BPC conducts HIV prevention and other studies that are relevant to the health of our South Bronx community, with a focus on studies about ways to decrease new HIV infections. Over the past decade, the BPC has established itself as a trusted partner within the South Bronx community by designing and implementing complex and varied HIV prevention studies and enrolling people in the neighborhoods where they live and work.

BPC studies new medications, including those in early development (phase 1 or 2), being tested in order to receive final FDA approval (phase 3), and those being tested for new uses or new populations (phase 4).  BPC worked on treatment, prevention and vaccine studies during the Covid-19 pandemic and assisted in studies of Mpox during the New York City outbreak of Mpox in 2022.  BPC is studying new health technologies such as Apps and online tools and new strategies to implement healthcare delivery, such as mobile health vans.  Current studies include the use of injectable, long-acting HIV prevention (pre-exposure prophylaxis [PrEP]), mobile technologies to improve PrEP uptake and adherence, and HIV prevention for people who use drugs.